MARKET

IGXT

IGXT

Intelgenx Technologies Corp
OTCMQB

Real-time Quotes | Nasdaq Last Sale

0.162
-0.013
-7.24%
Closed 13:49 06/30 EDT
OPEN
0.161
PREV CLOSE
0.175
HIGH
0.162
LOW
0.160
VOLUME
63.24K
TURNOVER
10.20K
52 WEEK HIGH
0.690
52 WEEK LOW
0.160
MARKET CAP
25.06M
P/E (TTM)
-2.4583
1D
5D
1M
3M
1Y
5Y
IIROC Trading Halt - IGX.DB
The following issues have been halted by IIROC:
CNW Group · 22h ago
Small Pharma, Cybin Among Top Psychedelic Movers Of Today
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 12.55% at $0.13
Benzinga · 06/09 21:19
ATAI Life Sciences, Mind Medicine Among Top Psychedelic Movers Of Today
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 3.55% at $0.36
Benzinga · 06/06 20:52
Psychedelic Stock Gainers And Losers From June 3, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 5.88% at $0.35
Benzinga · 06/03 20:37
Cybin, GH Research Among Top Psychedelic Movers Of Today
GAINERS: Cybin (AMEX:CYBN) shares closed up 9.50% at $0.75
Benzinga · 06/02 21:19
ATAI Life Sciences, Intelgenx Technologies Among Top Psychedelic Movers Of Today
GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 7.05% at $0.91
Benzinga · 06/01 21:00
IntelGenx Announces Intention to Issue Shares in Payment of Principal and Interest on Outstanding Debentures
SAINT LAURENT, Quebec, June 01, 2022 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) announces that it intends to (i) issue shares of common stock of the Company (“Shares”) in payment of the outstandin...
GlobeNewswire · 06/01 12:30
Psychedelic Stock Gainers And Losers From May 31, 2022
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 8.54% at $0.36
Benzinga · 05/31 20:37
More
No Data
Learn about the latest financial forecast of IGXT. Analyze the recent business situations of Intelgenx Technologies Corp through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average IGXT stock price target is 0.7964 with a high estimate of 0.7964 and a low estimate of 0.7964.
High0.7964
Average0.7964
Low0.7964
Current 0.1620
EPS
Actual
Estimate
-0.02-0.01-0.01-0.00
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 1
Institutional Holdings: 5.00K
% Owned: 0.00%
Shares Outstanding: 154.69M
TypeInstitutionsShares
Increased
0
0
New
1
5.00K
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.21%
Pharmaceuticals & Medical Research
-0.21%
Key Executives
Chairman/Chief Executive Officer/Director
Horst Zerbe
President/Chief Financial Officer
Andre Godin
Non-Executive Vice Chairman/Independent Director
J. Bernard Boudreau
Vice President - Operations
Rodolphe Obeid
Vice President/General Counsel
Tommy Kenny
Vice President - Research & Development
Nadine Paiement
Vice President - Business Development
Dana Matzen
Secretary
Ingrid Zerbe
Director
Srinivas Rao
Director
Frank Stegert
Independent Director
John Marinucci
Independent Director
Clemens Mayr
Independent Director
Bernd Melchers
Independent Director
Mark Nawacki
No Data
No Data
About IGXT
IntelGenx Technologies Corp is a Canada-based drug delivery company focused on the development of oral immediate-release and controlled-release products and on developing pharmaceutical products based on its drug delivery technologies. Its product development efforts are based upon over three delivery platform technologies, such as VersaFilm, an oral film technology; VersaTab, a multilayer tablet technology, and AdVersa, a mucoadhesive tablet technology. The VersaFilm technology consists of a thin (25 to 35 micron) polymeric film consisting of the United States Pharmacopeia (USP) components for use in food, pharmaceutical and cosmetic products. Its Multilayer Tablet platform technology allows for the development of oral controlled-release products. Its product portfolio includes INT0001/2004, INT0004/2006, INT0007/2006, INT0008/2007, INT0010/2006, INT0027/2011, INT0030/2011, INT0036/2013, INT0037/2013, INT0039/2013, INT0040/2014, INT0041/2015, INT0042/2015 and INT0043/2015.

Webull offers kinds of IntelGenx Technologies Corp. stock information, including OTCMQB:IGXT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IGXT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IGXT stock methods without spending real money on the virtual paper trading platform.